Poster Number	**Abstract Title and Authors**
[P2.1]	**Postpartum weight retention is neither enhanced by use of prenatal multiple micronutrient supplements nor by introducing food supplements in first trimester: findings from MINIMat trial in rural Bangladesh** A.M.W Hoque*[12], L.A. Persson[2], S.E. Arifeen[1], E.C. Ekstrom[2], [1]*ICDDR, Bangladesh;* [2]*Uppsala University, Sweden*
[P2.2]	**Enhancement of *in vivo* antimalarial activity of pyronaridine by promethazine in a mouse model** O.O. Abiodun*[1], G.O. Gbotosho[1], C.T. Happi[1], M.O. Falade[1], A.M.J. Oduola[2], [1]*University of Ibadan, Nigeria;* [2]*Special Program for Research and Training in Tropical Diseases (WHO/TDR), Switzerland*
[P2.3]	**Artesunate plus sulfadoxine–pyrimethamine in the treatment of uncomplicated *Plasmodium falciparum* malaria during pregnancy in eastern Sudan** I. Adam*[1], D. Ali[2], M. Abdalla[1], [1]*University of Khartoum, Sudan;* [2]*New Halfa Hospital, Sudan*
[P2.4]	**Malaria transmission in urban area: the contrast (Adzope, Cote d'Ivoire)** A.M. Adja*[1,2], S. Assi[1], A. Somian[1], A.A. Koffi[1], A.L Ahoua[1, 2] M. Kone[1], J.A. Djaman[2,3], [1]*Institut Pierre Richet, Cote d'Ivoire;* [2]*Université Cocody Abidjan, Cote d'Ivoire;* [3]*Institut Pasteur Abidjan, Cote d'Ivoire*
[P2.5]	**Malaria transmission in the western Kenya highlands: the impact of land use changes** Y.A Afrane*[1], B.W. Lawson[1], A.K. Githeko[2], G. Yan[3], [1]*Kenya Medical Research Institute, Kenya;* [2]*Kwame Nkrumah University of Science and Technology, Ghana;* [3]*University of California at Irvine, USA*
[P2.6]	**The influence of maternal request on the elective caesarean section rate in maternity hospitals in Tehran, Iran** A. Ahmadifar, G. Khoushehmehri, M. Moradian, *School of public Health & Institute of Public Health Researches, (SSRC), Iran*
[P2.7]	**Flavanones with antiplasmodial activity from *Erythrina abyssinica* family: *Fabaceae*** H.M. Akala[1], J. Wangui[1], P. Liyala[1], N.C. Waters[1], A.W. Andayi[2,3], A. Yenesew[2,] S. Derese[2], J.O. Midiwo[2], P.M. Gitu[2], O.J. I. Jondiko[3], T. Akenga[4], M. Heydenreich[5], M.G. Peters[5], [1]*Global Emerging Infections Surveillance and Response System (GEIS) Program, US Army Medical Research Unit-Kenya, Nairobi;* [2]*Department of Chemistry, University of Nairobi, Kenya;* [3]*Department of Chemistry, Maseno University, Kenya;* [4]*Department of Chemistry, Jomo Kenyatta University of Agriculture and Technology, Kenya;* [5]*Institute fur Chemie, Universitat Potsdam, Germany*
[P2.8]	**The imminent disappearance of the disease Kuru from Papua New Guinea** M.P. Alpers*[1], J Whitfield[2], J Collinge[3], D.C. Gajdusek[4], Kuru Surveillance Team[1], [1]*Institute of Medical Research, Papua New Guinea;* [2]*Curtin University of Technology, Australia;* [3]*UCL, UK;* [4]*Centre National de Rechetche Scientifique, France*
[P2.9]	**Malaria and malaria control in pregnancy in Marovo Lagoon, Solomon Islands** B. Appleyard*[1], M. Tuni[2], J. Bryan[1], J.S. McCarthy[1], [1]*Australian Centre for International and Tropical Health, Australia;* [2]*Solomon Islands Medical Training and Research Institute, Solomon Islands*
[P2.10]	**A fever study in the Gampaha district of Sri Lanka** M.S. Bailey*[1], M.T.W. Wijesuriya[2], N.R. de Silva[2], S.J. Peacock[3], D.G. Lalloo[4], H.J. de Silva[2], [1]*Army Medical Directorate, UK;* [2]*University of Kelaniya, Sri Lanka;* [3]*Mahidol-Oxford-Wellcome Tropical Medicine Unit, Thailand;* [4]*Liverpool School of Tropical Medicine, UK*
[P2.11]	**Measuring socioeconomic and health inequalities in rural Yemen: the poor versus the poor and the poor versus the national averages** S.M. Banajeh, *Sana'a University, Yemen*
[P2.12]	**Sero-epidemiology of viral hepatitis in Aden City, Yemen** A. Bawazir*, L. Cuevas, C. A. Hart, *Liverpool School of Tropical Medicine, UK*
[P2.13]	**Determination of lumefantrine after capillary sampling onto filter paper** D.B. Blessborn*[1], S.R. Römsing[1], A.N. Annerberg[2], Y.B. Bergqvist [1], D. Sundquist[1], A.B. Björkman[1], N.L. Lindegårdh[1], [1]*Dalarna University College, Sweden;* [2]*Mahidol University, Thailand;* [3]*Karolinska Institute, Sweden,*

[P2.14]	**Quality and immunogenicity of MenAfriVac: a conjugate vaccine against meningococcal group a disease** C. Mattick[1], A. Martino[1], C. Tiengwe[1], I.M. Feavers[1], S. Viviani[2], B Bolgiano*[1], *[1]National Institute for Biological Standards and Control, UK; [2]Path, France*
[P2.15]	**P-glycoprotein-like protein, a possible genetic marker to follow potential ivermectin resistance in *Onchocerca volvulus*** C. Bourguinat*[1], S.D.S. Pion[2], J. Kamgno[3], J. Gardon[4], B.O.L. Duke[5], M. Boussinesq[6], *[1]McGill University, Canada; [2]Laboratoire de Neuroparasitologie et neuroepidemiologie Tropicale, France; [3]Centre Pasteur Yaounde, Cameroon; [4]Institut de Recherche pour le Developement, Bolivia; [5]River Blindness Foundation, UK; [6]Institut de Recherche pour le Developpement, France*
[P2.16]	**Antiplasmodial activity of some constituents of the root bark of *Harungana Madagascariensis Iam.* (Hypericaceae)** B.N. Lenta[1], S.A. Ngouela[1], F.F. Boyom*[1], F. Tantangmo[1], G.R.F. Tchouya[1], E. Tsamo[1], J. Gut[2], P.J. Rosenthal[2], J.D. Connolly[3], *[1]University of Yaounde, Cameroon; [2]University of California, USA; [3]University of Glasgow , UK*
[P2.17]	**Reduction in child morbidity and mortality due to vaccine-preventable diseases in Uganda** F. Braka*[1], I. Makumbi[2], M. Nanyunja[1], W. Mbabazi[1], A. Kisakye[2], *[1]World Health Organization, Uganda; [2]Ministry of Health, Uganda*
[P2.18]	**Identification of secreted proteins from infective larvae and parasitic females of *Strongyloides ratti* with putative relevance for the parasitic form of life** H. Soblik*[1], H. Steen[2], M. Mitreva[3], P. Fischer[4], N.W. Brattig[1], *[1]Bernhard Nocht Institute for Tropical Medicine, Germany; [2]Children´s Hospital Boston, USA; [3]Genome Sequencing Center, Washington University, St. Louis, USA; [4]Washington University, USA*
[P2.19]	**Three new drugs for leishmaniasis: the story of liposomal amphotericin, miltefosine and paromomycin** A. Bryceson*, J. Berman, W. Gutteridge, J. Karbwang, *London School of Hygiene and Tropical Medicine, UK*
[P2.20]	**Risk factors for mortality from malaria: does resistance of *Plasmodium falciparum* explain the high mortality rate in Our Lady's Hospital, Chilonga, Zambia or are other factors involved?** M. Buijs*[1], J. van Rijn[1], P. Borsboom[2], J. Nouwen[1], *[1]Erasmus MC, Netherlands; [2]OLH Chilonga, Zambia*
[P2.21]	**Immunolocalization of actin in the different stages of *Trypanosoma cruzi*** A.M. Cevallos*[1], Y.X. Segura-Kato[1], H. Merchant-Larios[1], R. Manning-Cela[2], I. Lopez-Villasenor[1], R. Hernandez[1], *[1]UNAM, Mexico; [2]CINVESTAV, Mexico*
[P2.22]	**High malaria self-treatment in adolescent girls in rural Malawi** G.K. Chapotera*[1], B.J. Brabin[1,2], *[1]Liverpool School of Tropical Medicine, UK; [2]Royal Liverpool Children's NHS Trust, UK*
[P2.23]	**Relationships between microfilarial load and excess mortality of the human host in onchocerciasis** K. Wagner[1], M.P. Little[1], E.S. Alley[2], M-G. Basáñez*[1], *[1]Imperial College London, UK; [2]World Health Organization Regional Office for Africa, DR*
[P2.24]	**Malaria vector control and insecticide resistance** M. Coetzee*[1], R.H. Hunt[2], L.L. Koekemoer[1], B.D. Brooke[1], *[1]National Institute for Communicable Diseases, South Africa; [2]University of the Witwatersrand, South Africa*
[P2.25]	**Wing geometric morphometry for identification of *Rhodnius* spp. (*prolixus group*) (*hemiptera, reduviidae, triatominae*) in central Brazil** R.G.G. Gurgel-Gonçalves[2], C.A.C.C. Cuba Cuba*[1], *[1]Universidade de Brasília, Brazil; [2]Universidade Católica de Brasília, Brazil*
[P2.26]	**Human fascioliasis: age and gender distribution among the rural population of the Nile Delta, Egypt** F Curtale*[1], Y.A.W. Hassanein[2], A. El Wakeel[2], S. Mas-Coma[3], A. Montresor[4], *[1]Laziosanità - Agenzia di Sanità Pubblica, Italy; [2]Ministry of Health and Population, Egypt; [3]University of Valencia, Spain; [4]World Health Organization, Switzerland*

[P2.27]	**The use of community washing units to reduce transmission of water-borne diseases in Egypt** F. Curtale*[1], M. Raafat[2], A. El Wakeel[2], P. Barduagni[3], S. Pomiato[3], *[1]Laziosanità - Agenzia di Sanità Pubblica, Italy; [2]Ministry of Health and Population, Egypt; [3]Directorate General for Development Cooperation, Italy*
[P2.28]	**Review of supplementing mass drug administration against filariasis with vector control** C.F. Curtis, *London School of Hygiene & Tropical Medicine, UK*
[P2.29]	**Immunization using *L. donovani* phosphoproteins protects BALB/c mice against experimental VL infection** P. Das*[1], S. Sundaram[2], S. Bimal[3], S.K. Singh[3], P. Das[3], *[1]Institute for One World Health, India; [2]University of Allahabad, India; [3]Rajendra Memorial Research Institute of Medical Sciences (ICMR), India*
[P2.30]	**A cluster randomised trial to test the impact of deltamethrin dog collars on the incidence of zoonotic visceral leishmaniasis in Iran** C.R. Davies*[1], A.S. Mazloumi Gavgani[2], *[1]London School of Hygiene & Tropical Medicine, UK; [2]Tabriz University of Medical Sciences, Iran*
[P2.31]	**Investigation of IFN-γ responsiveness in a longitudinal cohort of malaria-exposed, semi-immune Papa New Guinean children** M.C. D'Ombrain*[1], L.J. Robinson[1], C. King[2], D. Stanisic[1], I. Mueller[3], L. Schofield[1], *[1]The Walter & Eliza Hall Institute of Medical Research, Australia; [2]Case Western Reserve University, USA; [3]Papua New Guinea Institute of Medical Research, Papua New Guinea*
[P2.32]	**Inflammatory mononuclear phagocyte in leishmaniasis: phenotypes and adhesion-molecule expression** M.D.E-R. Hermida, R. Malta, M.P. Macedo, M.A. Maciel, J.O. Mengel, W.L.C. dos-Santos*, *Centro de Pesquisas Goncalo Moniz-Fundacao Oswaldo Cruz, Brazil*
[P2.33]	**Expanding the use of serological markers of malaria exposure for estimating malaria-transmission intensity** C. Drakeley*[2], P. Corran[3], J. Cook[1], E. Riley[1], *[1]LSHTM, UK; [2]Joint Malaria Programme, Tanzania; [3]NIBSC, UK*
[P2.34]	**Dendrimer-based targeted drug delivery for effective management of tropical diseases** T. Dutta, R.K. Tekade, V. Dubey, N.K. Jain*, *Dr H. S. Gour University, India*
[P2.35]	**Cross-protection studies with *Onchocerca volvulus*-glyceraldehyde-3-phosphate dehydrogenase in the *Litomosoides sigmodontis*/mouse model and the *Strongyloides ratti*/rat model** V. Steisslinger, S. Korten*, K. Erttmann, *Bernhard-Nocht-Institute for Tropical Medicine, Germany*
[P2.36]	**Mortality in HIV-infected and uninfected severely malnourished children** P. Fergusson*[1], J. Chinkhumba[2], A. Tomkins[3], *[1]University of Chester, UK; [2]Action Against Hunger, Malawi; [3]Centre for International Health and Development, UK*
[P2.37]	**Molecular genotyping of human cytomegalovirus strains circulating in Honduran and Costa Rican populations** A. Ferrera*[1], L. Herrero-Uribe[2], K. Visona[3], *[1]Universidad Nacional Autónoma de Honduras, Honduras; [2]University of Costa Rica, Costa Rica; [3]Louisiana State University-International Center for Medical Research and Training, Costa Rica*
[P2.38]	**Presence of light-chain dyneins in *Schistosoma mansoni* tegument** E. K. Githui*[1], R. A. Aman[1], R. T. Damian[2], M. A. Ali[1], *[1]National Museums of Kenya, Kenya; [2]University of Georgia, USA*
[P2.39]	**Dengue outbreak in healthcare workers during an epidemic in Delhi** V. Gupta*, A. Goel, S. Bhoi, P. Aggarwal, *All India Institute of Medical Sciences, India*
[P2.40]	**Clinical profile of dengue outbreak in Delhi (2004–2005)** V. Gupta*, S. Bhoi, A. Goel, P. Aggarwal, *All India Institute of Medical Sciences, India*
[P2.41]	**Leprosy patients attending the outpatient's clinic at Agra: a retrospective analysis of the characteristics and frequency of regularity vs irregularity for determining absenteeism, non-adherence and non-compliance** V.S. Yadav*, K. Katoch, T. Hussain, *National JALMA Institute for Leprosy and Other Mycobacterial Diseases (Indian Council of Medical Research), India*

[2.42]	**Tentative interaction between two major malaria species: a possible role of Toll-like receptors in mixed malaria infection** K. Jangpatarapongsa*[1], S. Chuangchaiya[1,2], J. Sattabongkot[3], J. Sirichaisinthop[4], M. Troye-Blomberg[5], *[1]Mahidol University, Thailand; [2]Armed Forces Research Institute of Medical Sciences, Thailand; [3]Ministry of Public Health, Thailand; [4]Stockholm University, Sweden; [5]The Pennsylvania State University, USA*
[P2.43]	**The status of anisakids larvae among fish of Qatar, Arabian Gulf and the increasing of prevalence due to environmental stress** M. Kardousha, *University of Qatar, Qatar*
[P2.44]	**Genetic diversity of *Plasmodium vivax* isolates from Sri Lanka** N.D. Karunaweera*[1], M.U. Ferreira[2], D.L. Hartl[3], D.F. Wirth[4], *[1]Faculty of Medicine, University of Colombo, Sri Lanka; [2]University of Sao Paulo, Brazil; [3]Harvard University, USA, Harvard School of Public Health, USA*
[P2.45]	**Authentication of antimalarial drug formulations for use in Africa** H. Kaur, *London School of Hygiene & Tropical Medicine, UK*
[P2.46]	**Remember Bombali: the end of the trial** A. Kelly*[1], P.W. Geissler[1], R. Pool[1], E.B. Imoukhuede[2], *[1]London School of Hygiene and Tropical Medicine, UK; [2]European Malaria Vaccine Initiative, UK*
[P2.47]	**The multiplicity of malaria transmission: entomological inoculation rates and case studies across sub-Saharan Africa** L.A. Kelly-Hope*[1], F.E. McKenzie[2], *[1]Liverpool School of Tropical Medicine, UK; [2]National Institutes of Health, USA*
[P2.48]	***Leishmania major* trans-glycosylation** A. Khabiri, *Pasteur Institute of Iran, Iran*
[P2.49]	**Modelling malaria transmission in Thailand and Indonesia** R. Kiang*, F. Adimi, J. Nigro, *NASA Goddard Space Flight Center, USA*
[P2.50]	**Seroepidemiology of HBV–HIV coinfection in Tunisia** B. Kilani*, A. Berriche, L. Ammari, H. Tiouiri Benaïssa, *Rabta Hospital, Tunisia*
[P2.51]	**To evaluate the existing tuberculosis (TB) surveillance and monitoring systems of the Community-Based Directly Observed Treatment Short course (CB DOTS) program in Rakai district, Uganda and recommend future improvements in planning and service delivery** D. Kiragga, *Plan Uganda, Uganda*
[P2.52]	**Impact of temporal-spatial variations of malaria incidence on the protective efficacy of intermittent preventive antimalarial treatment of infants (IPTi)** R. Kobbe*[1], B. Kreuels[1], S. Adjei[2], W. Busch[1], O. Adjei[2], J. May[1], *[1]Bernhard Nocht Institute for Tropical Medicine Hamburg, Germany; [2]Kumasi Centre for Collaborative Research in Tropical Medicine, Ghana*
[P2.53]	**Macrofilaricidal therapy induces local Foxp3+ regulatory T cells, granzyme-B expression and senescent CD57+ T cells in onchocerciasis** S. Korten*, M. Badusche, B. Fleischer, *Bernhard Nocht Institute for Tropical Medicine, Germany*
[P2.54]	**Opening the Pandora's box of the enigmatic protozoan parasite, *Blastocytis hominis*** K. Suresh *[1], T.C. Tan [1], S. Shuba [1], S.C. Ong[1], H.V. Smith[2], *[1]University Malaya , Malaysia; [2]Scottish Parasite Diagnostic Laboratory, UK*
[P2.55]	**The millennium goals need new vaccines and drugs for HIV, malaria and TB. Are we ready and able to conduct the trials in developing countries to truly assess the new drugs and vaccines coming through the development pipelines?** T. Lang*[12], K. Marsh[12], *[1]KEMRI-WELLCOME Programme, Kenya; [2]University of Oxford, UK*
[P2.56]	**How high does the peak concentration of artesunate need to be to efficaciously cover *P. falciparum*-infected RBCs in humans?** Q.G. Li*, P.J. Weina, W.K. Milhous, *Walter Reed Army Institute of Research, USA*
[P2.57]	**Study of the risk of introduction of the cutaneous leishmaniasis into the area of Sidi Slimane (Province of Kénitra)** L. Majda*[1], B. Driss[2], R. Mohammed [1], L. Mohammed[1], O. Souad[1], *[1]Institut National Hygiène in Rabat , Morocco; [2]University Ibn Tofail Kénitra , Morocco*

[P2.58]	**Indirect costs of animal bite on household in Sri Lanka communities** G.C. Matibag*[1], R.A. Ditangco[12], T. Kamigaki[1], P.V.R. Kumarasiri[3], T.G. Wijewardana[3], H. Tamashiro[1], *[1]Hokkaido University Graduate School of Medicine, Japan; [2]Research Institute for Tropical Medicine, Philippines; [3]University of Peradeniya, Sri Lanka*
[P2.59]	**Rabies-related risk factors after animal bites in communities in Sri Lanka** R.A. Ditangco*[12], G.C. Matibag[1], T. Kamigaki[1], P.V.R. Kumarasiri[3], T.G. Wijewardana[3], H. Tamashiro[1], *[1]Hokkaido University Graduate School of Medicine, Japan; [2]Research Institute for Tropical Medicine, Philippines; [3]University of Peradeniya, Sri Lanka*
[P2.60]	**Differential cytokine responses of peripheral blood mononuclear cells from new world cutaneous leishmaniasis patients and subjects vaccinated with a first generation vaccine to crude and defined *Leishmania amazonensis* antigens** R. B. Azeredo-Coutinho[1], D. Matos[1], G. Armôa[1], A. Schubach[1], W. Mayrink[1], S. Mendonça*[12], *[1]Fundação Oswaldo Cruz, Brazil; [2]Universidade Federal de Minas Gerais, Brazil*
[P2.61]	**Association between the infection by *Helicobacter pylori* and intestinal parasitism** V. Ruíz-Álvarez[1], M. Hernández Triana[1], R. Junco Díaz[2], L.T. Menocal Heredia[2], A.M. Collado Madurga[2], M. Wördemann[3], R. Cordoví Prado*[4], *[1]Institute of Nutrition and Hygiene of Foods, Cuba; [2]National Institute of Hygiene, Cuba; [3]Prince Leopold Institute of Tropical Medicine, Belgium; [4]Pedro Kourí Institute of Tropical Medicine, Cuba*
[P2.62]	**Overlooking undernutrition? Using a composite indicator of anthropometric failure (CIAF) to assess how underweight misses and misleads the assessment of undernutrition in young children** S. Nandy[1], J. J. Miranda*[2], *[1]University of Bristol, UK; [2]London School of Hygiene and Tropical Medicine, UK*
[P2.63]	**Evaluation and validation of immuno-diagnostic tests for kala-azar** T.M. Mohapatra*, K. Bharti, M.R. Sen, S. Sunder, *Institute of Medical Sciences, India*
[P2.64]	**Predictors of poor outcome in malaria- A clinical study in a tertiary referral centre in a malaria-endemic area, Kolar District, India** N. Moorthy*, P.N. Venkatarathnamma, *Sri Devaraj Urs Medical college and RLJ Hospital and Research Centre, India*
[P2.65]	**Religion and ARV treatment: managing ART among Muslim patients in rural Guinea** A. Keita[1], D. Keita[2], M. Kowaleswki[3], F. Ndonko*[4], *[1]Mamou Regional Hospital, Guinea; [2]GFA-GTZ, Guinea; [3]GFA, Germany; [4]GTZ, Cameroon*
[P2.66]	***Trichinellosis* among children in a Romanian western county during the period 1990–2006** R. Neghin[1,2], [1]*Victor Babes" University of Medicine and Pharmac, Romania; [2]Banat University of Agricultural Sciences and Veterinary Medicine, Romania*
[P2.67]	**Quantifying the epidemiology of an eradicated disease: project of complete parameterization of smallpox** H. Nishiura*[1], M. Eichner[2], *[1]Nagasaki University Institute of Tropical Medicine, Japan; [2]University of Tubingen, Germany*
[P2.68]	**The epidemiology of malaria and malnourishment in rural Muea on the slope of Mount Cameroon** T.K. Nkuo Akenji*, I.N. Sumbele, E. Manka, M. Samje, *University of Buea, Cameroon*
[P2.69]	**How sulfadoxine-pyrimethamine (SP) was perceived in rural communities of Tanzania after phasing out chloroquine as a first-line drug for uncomplicated malaria** S. Nsimba, *Muhimbili University College of Health Sciences (MUCHS), Tanzania*
[P2.70]	**Differential *Plasmodium falciparum* infection rates and permethrin susceptibility status of *Anopheles gambiae* in urban and rural communities in Nigeria** A.O. Oduola*[1,2], A. Otubanjo[2], J.O Oyewole[3], J.B Obansa[1], T.S. Awolola[1], *[1]Nigerian Institute of Medical Research; [2]Nigeria University of Lagos, Nigeria; [3]Babcock University, Nigeria*
[P2.71]	**Acquisition of bed-nets, sleeping-habits and control of malaria in the Gambia: sociocultural dimension** B.J. Okoko, *Medical Research Council, Gambia, The*

[P2.72]	**Evaluation of different protocols for the elicitation of murine immune responses to a new *Leishmania chagasi/infantum* recombinant antigen** L.R. dos Santos*[1,2], R.E. Fraga[1,2], A.M. Pereira[2], D.M. Santos[1], V.C. Sant'Ana Filho[1], L.C. Pontes-de-Carvalho[2], G.G.S. Oliveira[2], *[1]Fundacao Oswaldo Cruz, Brazil; [2]Universidade Federal da Bahia, Brazil*
[P2.73]	**Determination of indices for evaluation of interventions on maternal and child health in Nigeria** M. I. Oseji, *Delta State Ministry of Health, Nigeria*
[P2.74]	**Maternal and newborn care and outcomes in Mumbai slums** N. Shah More[2], S. Barnett[1], U. Bapat[2], S. Das[2], B. Tank[2], A. Fernandez[1], D. Orisin*[1], *[1]UCL, UK; [2]Education and Health Action, India*
[P2.75]	**IL-18 and IL-18Rα promoter polymorphisms and disease susceptibility in *P. falciparum*-infected children in Nigeria** S.I. Oyedeji*[1], H.O. Awobode[1], G.C. Monday[2], P.G. Kremsner[3], J.G. Kun[3], *[1]University of Ibadan, Nigeria; [2]Nasarawa State Ministry of Health, Nigeria; [3]Eberhard Karls University, Germany*
[P2.76]	**C-reactive protein, proinflammatory cytokines and inhibitors in typhoid fever** C.M Parry[1,4,5,*], N. T. Chinh[2], H. Vinh[2], V. A. Ho[3], D. House[1,6], T. S. Diep[2], P. V. Be Bay[3], J. Wain[1,4,6], T.T. Hien[2], C. A. Hart[5], J. J Farrar[1,4], *[1]University of Oxford Welcome Clinical Research Unit; [2]Hospital for Tropical Diseases, Ho Chi Minh City; [3]Dong Thap Provincial Hospital, Cao Lanh, Dong Thap Province, Vietnam; [4]Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford; [5]Department of Medical Microbiology and Genitourinary Medicine, University of Liverpool, Liverpool; [6]The Welcome Trust Sanger Institute, UK*
[P2.77]	**Assessment of optimal channels of communication for effective message delivery on Nagana and human African trypanosomiasis (HAT) in eastern and central Uganda** J. Fyfe*[1], C. Waiswa[2], E. Katunguka-Rwakishaya[2], F. Kasiime[3], S. Thorp[4], S. Welburn[1], *[1]University of Edinburgh, UK; [2]University of Makerere, Uganda; [3]COCTU, Uganda; [4]Wren Media, UK*
[P2.78]	**Paragonimus in Zhrjiang: morphology and molecular biology** B.Z. Qian, *Zhejiang Academy of Medical Sciences, China*
[P2.79]	**The cuses of severe febrile illness in children admitted to a district hospital in East Africa** B. Nadjm*[1], G. Mtove[2], B. Amos[3], H. Reyburn[1], *[1]London School of Hygiene and Tropical Medicine, UK; [2]National Institute for Medical Research, Tanzania; [3]Teule Hospital, Tanzania*
[P2.80]	**Monkeypox awareness and prevention: using mobile media for disease-prevention messages in remote, at-risk communities in the Republic of the Congo** M.G. Reynolds*[1], E.R. Lederman[1], J.V. Mombouli[2], C. Moses[3], R. Regnery[1], I.K. Damon[1], *[1]Centers for Disease Control and Prevention, USA; [2]Ministry of Health and Populations, USA; [3]International Conservation and Education Fund, USA*
[P2.81]	**A model for the impact of intermittent preventive treatment in infants on malaria morbidity and mortality** A. Ross*, N. Maire, M. Penny, A. Studer, T. Smith, *Swiss Tropical Institute, Switzerland*
[P2.82]	**Molecular cloning of excretory-secretory antigens encoding genes from the liver fluke, *Opisthorchis viverrini*** J. Ruangsittichai*[1], V. Viyanant[2], S. Vichasri-Grams[1], P. Sobhon[1], S. Tesana[3], A. Hofmann[4], *[1]Mahidol University, Thailand; [2]Thammasat University, Thailand; [3]Khon Kaen University, Thailand; [4]Freie Universität Berlin, Germany*
[P2.83]	**Neonatal malaria: Probable immune system modulation by *Plasmodium falciparum* infection** A. Khalil, *Khartoum, Sudan*
[P2.84]	**Impact assessment of insecticide-treated bednet usage on parasitaemia and anaemia for malaria control in children, Ogun State, Nigeria** P.O. Adah*, C.F. Mafiana, S.O. Sam-Wobo, *University of Agriculture, Nigeria*
[P2.85]	**Prevalence and patterns of tuberculosis in a cohort of hospitalised Sri Lankan HIV(+) individuals** D.D.A. Wijewickrama*[1], S. Navas[1], H.K.M.S. Silva[1], L.W.D.S. Perera[2], J. Perera[2], S.L. Seneviratne[3], *[1]Infectious Diseases Hospital, Sri Lanka; [2]University of Colombo, Sri Lanka; [3]Manchester Royal Infirmary, UK*

[P2.86]	**Interventions lead to reduction in morbidity and mortality rates among hospitalised patients with VZV infections in Sri Lanka** D.D.A. Wijewickrama*[1], S. Navas[1], L.W.D.S. Perera[2], P.M.I.P. Bandara[1], S.L. Seneviratne[3], J. Perera[2], *[1]Infectious Diseases Hospital, Sri Lanka; [2]Department of Microbiology, University of Colombo, Sri Lanka; [3]Department of Clinical Immunology, Manchester Royal Infirmary, UK*
[P2.87]	**Prevalence of *pfATPase6* gene mutations in *Plasmodium falciparum* isolates from Africa** M. Menegon*[1], A.R. Sannella[1], W.O. Inojosa[2], P.M. Abel[3], A. Matondo[4], Z. Bisoffi[5], *[1]Istituto Superiore di Sanità, Italy; [2]CUAMM-Angola, Angola; [3]Caritas, Angola; [4]Provincial Hospital, Angola; [5]Sacro Cuore Hospital of Negrar, Italy; [6]London School of Hygiene and Tropical Medicine, UK*
[P2.88]	**Prevalence of orphaned HIV-infected children – a preliminary study from India** I. Shah, *B.J.Wadia Hospital for Children, India*
[P2.89]	**Lessons from 1918: simultaneous pandemic influenza and malaria epidemics during World War I** G.D. Shanks*, *Army Malaria Institute, Australia*
[P2.90]	**Structure of P25 proteins from *Plasmodium* and their interaction with transmission blocking antibodies: a molecular modeling and docking study** A. K. Saxena, B. Sharma*, R. Dev Ambedkar, *Jawaharlal Nehru University, India*
[P2.91]	**Cervical squamous intraepithelial lesions in HIV/AIDS: a retrospective review of 200 smears** T.L. Shiramba, G.Z. Mutuma, J.M. Kabanga, J. K. Kuria, H.A. Lodenyo*, *KEMRI, Kenya*
[P2.92]	**Prevalence of malaria parasitaemia in booking antenatal patients in a new Lagos State University Teaching Hospital (LASUTH)** A.O. Tayo*[1], I.A.I. Shittu[1], i. Akinola[1], M.A. Bankole[1], R.K. Shittu[2], O. Ogundipe[3], M.N. Bankole[4], *[1]Lagos State University, Nigeria; [2]Bolomedics Laboratories, Nigeria; [3]Obafemi Awolowo University, Nigeria; [4]Nigerian Institute of Medical Research, Nigeria*
[P2.93]	**Effect of pre-treatment chloroquine levels on parasitological response in children with acute uncomplicated malaria** A. Sijuade*, G. Gbotosho, T . Happi, A. Sowunmi, A. Oduola, *WHO, Switzerland*
[P2.94]	**Human visceral leishmaniasis: risk factors of acquiring the disease in Margarita Island, Venezuela** R.R. Silva Basanta*[1], R. Borges[2], M. Ulrich[2], *[1]Universidad Central de Venezuela, Venezuela; [2]Instituto de Biomedicina, Venezuela*
[P2.95]	**CD2-induced T-cell proliferation – an emerging trend in immune therapy against visceral leishmaniasis** S. Sinha*[1], S. Bimal[2], S. Sundaram[1], *[1]Allahabad University, India; [2]Rajendra Memorial Institute of Medical Sciences, India*
[P2.96]	**How is multiple care-seeking behaviour likely to impact the delivery of structured treatment packages and the equity of treatment outcomes?** J. Skordis-Worrall*, S. Martin, *Centre for International Heath at the Institute of Child Health, UK*
[P2.97]	**Schistosomiasis in African infants and preschool children: to treat or not to treat?** J.R. Stothard*[1], A.F. Gabrielli[2], *[1]Natural History Museum, UK; [2]World Health Organization, Switzerland*
[P2.98]	**Creating a global database of antimalarial resistance** C.H. Sibley[1], C.J. Sutherland[2], C. Roper*[2], *[1]University of Washington, USA; [2]London School of Hygiene & Tropical Medicine, UK*
[P2.99]	**Efficacy of a voluntary HIV and hepatitis prevention programme in the absence of legal access to needles and syringes among drug users in Uppsala County, Sweden** P.E.S. Sylvan*[1], J. Hedlund[1], B. Ardung[1], *[1]Dept of Communicable Disease Control and Prevention, Sweden; [2]Akademiska sjukhuset, Sweden; [3]Uppsala Social Services Administration, Sweden; [4]Uppsala Prison and Probation Administration, Sweden; [5]Uppsala Police Authority, Sweden*
[P2.100]	**Prevalence of carriage of group b streptococcus (GBS) in pregnant women in Maputo, Mozambique** F.D.O. de Steenwinkel[1], H.V. Tak*[1], A.E. Muller[2], J.L. Nouwen[3], P.M. Oostvogel[4], S.M. Mocumbi[5] *[1]University Medical Center Rotterdam, Netherlands; [2]Medisch Centrum Haaglanden, Netherlands; [3]Central Hospital Maputo, Mozambique*

[P2.101]	**Handbook of diagnosis, treatment and follow-up recommendations for *Trypanosoma cruzi*–HIV coinfection** S. O. Santos[1]*, E. Tatto[1], A. N. Ramos Jr[2], M. F. Simão[3], M. A. Shikanai-Yasuda[4], G. F. Pereira[1] *[1]Secretariat of Health Surveillance (SVS), Ministry of Health (MoH),– Brazil; [2] Federal University of Ceará; [3]Federal University of Uberlândia; [4]São Paulo University, Brazil*
[P2.102]	**Pattern of eclampsia at a semi-rural tertiary health facility in northern Nigeria** J. Tukur*[1], B.A. Umar[2], A. Rabi'u[2], *[1]Aminu Kano Teaching Hospital, Nigeria; [2]Federal Medical Center, Nigeria*
[P2.103]	**RCH in primitive tribes of central India: barrier to MDG** A. Verma*, D. Kumar, *Regional Medical Research Centre for Tribals, India*
[P2.104]	***Entamoeba invadens*: specific inhibitors of N-glycan processing α-glycosidases block encystation** L.M. Almanza-Villegas*, E. López-Romero, J.C. Villagómez-Castro, *Universidad de Guanajuato, Mexico*
[P2.105]	**Ultrasound follow-up for human cystic echinococcosis** Y. Wang*[1], X. Zhang[1], M. Rogan[2], P. Craig[2], *[1]Xinjiang Medical University, China; [2]Salford University, UK*
[P2.106]	**Vitamin D as supplementary treatment for tuberculosis – a double-blind randomised placebo-controlled trial** C. Wejse[1,2], V.F. Gomes[1], P. Rabna[1], P. Gustafson[1,3], P. Aaby[1], I.M. Lisse[4], P.L. Andersen[2], H. Glerup[5], M. Sodemann[1,6], *[1]Bandim Health Project, INDEPTH Network, Statens Serum Institut; [2]Infectious Disease Research Unit, University Hospital, Denmark; [3]Infectious Diseases Research Group, Department of Clinical Sciences, Lund University, Sweden; [4]Dept. of Pathology, University Hospital, Denmark; [5]Dep. of Internal Medicine, University Hospital, Denmark; [6]Department of Epidemic Diseases, Copenhagen University Hospital, Denmark*
[P2.107]	**Therapeutic efficacy of chloroquine for uncomplicated *Plasmodium vivax* malaria in Sri Lanka** R. Wickremasinghe*[1], G. Galappathy[2], A. Wickremasinghe[3], P. Ringwald[1], *[1]University of Kelaniya, Sri Lanka; [2]Anti Malaria Campaign, Sri Lanka; [3]World Health Organization, Swaziland*
[P2.108]	**Neutrophil-mediated innate immune resistance to mycobacteria** A.R. Martineau[1], S.M. Newton[1], K.A. Wilkinson[3], B. Kampmann[1], B.M. Hall[2], R.J. Wilkinson*[1], *[1]Imperial College London, UK; [2]Queen Mary's School of Medicine and Dentistry London, UK; [3]University of Cape Town, South Africa; [4]Northwick Park Hospital, UK*
[P2.109]	**Has choice of diagnostic algorithm influenced the observed decline in incidence of human African trypanosomiasis in Angola?** P. Abel[1], C. Woodrow*[2], A. Stich[3], T. Josenando[4], S. Krishna[2], *[1]ANGOTRIP, Angola; [2]University of London, UK; [3]Medical Mission Institute, Germany; [4]ICCT, Angola*
[P2.110]	**Spurious human infection with *Gongylonema sp.*: nine cases reported from Surin province, Thailand** R. Yaicharoen*, S. Pasuralertsakul, S. Sripochang, *Mahidol University, Thailand*
[P2.111]	**Potent antimalarial and transmission-blocking activities of a novel DNA-binding agent** S.K. Yanow*[1], L.A Purcell[2], A. Rodriguez[3], M. Lee[4], T.W. Spithill[2], G. Pradel[3], *[1]Provincial laboratory of Public Health (Microbiology), Canada; [2]McGill University, Canada; [3]New York University, USA; [4]Hope College, USA*
[P2.112]	**Effects of vitamin A and iron supplementation on the treatment of malaria in Cameroonian preschool children** D. Zofou*, C.M. Teugwa, P.H. Amvam Zollo, *University of Yaounde I, Cameroon*
[P2.113]	**An epidemiological survey of multiple parasitic infections in rural and peri-urban settings in Hunan province, China** J Balen[1,2], DP McManus[1], G Raso[1,2], ZY Zhao[3], G Williams[2], J Utzinger[4], YS Li[1,3]. *[1]Queensland Institute of Medical Research, Australia; [2]University of Queensland, Australia; [3]Hunan Institute of Medical Research, China; [4]Swiss Tropical Institute, Switzerland*
[P2.114]	**A pre-erythrocytic malaria candidate vaccine based on a simian adenovirus** G. A. O'Hara[1], A. Reyes-Sandoval[1], R. Rowland[1], P. Bird[1], E. Berrie[1], A. Nicosia[2], S. Colloca[2], R. Cortese[2], L. Siani[2], A. Lawrie[1], S. Gilbert[1], A.V.S. Hill[1] *[1]University of Oxford, Oxford, UK; [2]Okairos AG, Italy*